Repository logo
 
No Thumbnail Available
Publication

Recombinant human erythropoietin treatment in a rat model of nephrectomy

Use this identifier to reference this record.
Name:Description:Size:Format: 
56 Recombinant human erythropoietin ECP 15.pdf3.82 MBAdobe PDF Download

Advisor(s)

Abstract(s)

We aimed to evaluate the impact of rHuEPO on anemia, renal function and structure in chronic renal failure (CRF), using a rat model of nephrectomy. Male Wistar rats, 12 weeks old, were divided in 3 groups: CRF (induced by a two-stage 5/6 nephrectomy); rHuEPO-CRF (treated with 100 IU/kg/week during 3 weeks) and Sham (surgery without mass reduction). Hematological and biochemical studies were performed. Kidney tissue sections were stained with Periodic acid-Schiff for histological studies. Statistical analysis were performed using the Mann-Whitney test. At the end of protocol, CRF group presented anemia (p<0.05) and reduced glomerular filtration rate (GFR), whereas rHuEPO-CRF group showed an improvement in hematological parameters (p<0.05) and a slight improvement in GFR. The histopathological analysis of kidney tissue showed that CRF group presented global glomerulosclerosis, tubular necrosis, IFTA and arteriolosclerosis. Due to surgery, we also found some inflammatory cell infiltration. The rHuEPO-CRF group presented mesangial expansion and a reduction in tubulointerstitial and vascular lesions, as compared to CRF rats. The introduction of rHuEPO corrects the anemia associated with renal failure and improved the degree of renal lesions, slowing the progress of renal failure.

Description

Keywords

rHuEPO anemia rat model of nephrectomy

Pedagogical Context

Citation

Sandra Ribeiro Helena Vala, Patrícia Garrido, João Fernandes, Elísio Costa, Luís Belo, Flávio Reis, Alice Santos- Silva (2015). Recombinant human erythropoietin treatment in a rat model of nephrectomy. Virchows Arch 467 (Supll I): S32 IF 2012 2.676

Research Projects

Organizational Units

Journal Issue